• S Myou, M Fujimura, K Kurashima, H Tachibana, T Hirose, and S Nakao.
• The Third Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa, Ishikawa, Japan.
• Clin. Exp. Allergy. 2000 May 1;30(5):713-8.

BackgroundAlthough phosphodiesterase (PDE) 3 and 4 inhibitors have received much attention for the treatment of bronchial asthma, systemic adverse effects have also been reported.ObjectiveThe purpose of this study was to investigate the effect of inhaled olprinone, a newly developed PDE3 inhibitor, and KF19514, a PDE1 and 4 inhibitor, on antigen-induced airway reactions in guinea-pigs.MethodsFifteen minutes after inhalation of olprinone (0.1 or 1.0 mg/mL) and KF19514 (0.1 or 0.01 mg/mL), animals were given an antigen challenge. Bronchial hyper-responsiveness and bronchoalveolar lavage fluid cell analysis were performed 24 h after the antigen challenge.ResultsInhalation of olprinone and KF19514 caused a dose-related inhibition of antigen-induced bronchoconstriction. Antigen inhalation significantly increased bronchoconstrictor responses to methacholine, and airway accumulation of neutrophils and eosinophils, 24 h after the antigen challenge. These responses were dose-dependently prevented by KF19514, but not by olprinone.ConclusionThe results indicate that inhaled PDE inhibitors might be useful for treatment of bronchial asthma.

42 keywords...

hide…